Corcept Therapeutics Incorporated (CORT)

Market Cap	7.85B
Revenue (ttm)	675.04M
Net Income (ttm)	139.73M
Shares Out	105.50M
EPS (ttm)	1.23
PE Ratio	60.53
Forward PE	43.92
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,539,754
Open	77.60
Previous Close	79.37
Day's Range	72.64 - 78.00
52-Week Range	20.84 - 117.33
Beta	0.15
Analysts	Strong Buy
Price Target	143.25 (+92.41%)
Earnings Date	Apr 30, 2025

About CORT

Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing’s syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical t...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 500
• Stock Exchange: NASDAQ
• Ticker Symbol: CORT
• Website: https://www.corcept.com

Financial Performance

In 2024, Corcept Therapeutics's revenue was $675.04 million, an increase of 39.94% compared to the previous year's $482.38 million. Earnings were $139.73 million, an increase of 32.45%.

Analyst Forecast

According to 4 analysts, the average rating for CORT stock is "Strong Buy." The 12-month stock price forecast is $143.25, which is an increase of 92.41% from the latest price.

Price Target

$143.25

(92.41% upside)

Analyst Consensus: Strong Buy